Cargando…

Reasons for refusing parenteral therapy: a qualitative study of patients with pulmonary arterial hypertension

While parenteral prostacyclin (pPCY) therapy, delivered either subcutaneously or intravenously, is recommended for pulmonary arterial hypertension patients with severe or rapidly developing disease, some patients refuse this treatment. This study aimed to understand, directly from patients with pulm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morland, Kellie, Raina, Amresh, Nails, Abigail, Classi, Peter, Etschmaier, Martine, Frantz, Robert P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743947/ https://www.ncbi.nlm.nih.gov/pubmed/35024138 http://dx.doi.org/10.1177/20458940211046761

Ejemplares similares

Inhaled treprostinil vs iloprost: Comparison of adherence, persistence, and health care resource utilization in patients with pulmonary arterial hypertension
por: Burger, Charles D, et al.
Publicado: (2023)

Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
por: Raina, Amresh, et al.
Publicado: (2013)

Risk assessment in pulmonary arterial hypertension
por: Raina, Amresh, et al.
Publicado: (2016)

Safety and efficacy of transitioning from the combination of bosentan and sildenafil to alternative therapy in patients with pulmonary arterial hypertension
por: Verlinden, Nathan J., et al.
Publicado: (2020)

A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost
por: Channick, Richard N., et al.
Publicado: (2013)

Identifying Patients with Group 3 Pulmonary Hypertension Associated with COPD or ILD Using an Administrative Claims Database
por: Heresi, Gustavo A., et al.
Publicado: (2022)

Impact of Parenteral Prostanoids in Pulmonary Arterial Hypertension: The Relevance of Timing
por: Papa, Silvia, et al.
Publicado: (2023)

Refusals to perform ritual circumcision: a qualitative study of doctors’ professional and ethical reasoning
por: Litleskare, Liv Astrid, et al.
Publicado: (2020)

Reasons for Refusing Home-based Palliative Care: A Qualitative Study of Patients and Caregivers
por: Cardenas, Valeria, et al.
Publicado: (2020)

Hemodynamic monitoring in heart failure and pulmonary hypertension: From analog tracings to the digital age
por: Davey, Ryan, et al.
Publicado: (2016)

Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients
por: Aldweib, Nael, et al.
Publicado: (2021)

Association between cytokines and functional, hemodynamic parameters, and clinical outcomes in pulmonary arterial hypertension
por: Joshi, Aditya A., et al.
Publicado: (2018)

Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series
por: Raina, Amresh, et al.
Publicado: (2017)

Data on clinical and economic burden associated with pulmonary arterial hypertension related hospitalizations in the United States
por: Chaturvedi, Abhishek, et al.
Publicado: (2020)

COVID-19 Vaccination Willingness and Reasons for Vaccine Refusal
por: Lun, Phyllis, et al.
Publicado: (2023)

What are the reasons for refusing a COVID-19 vaccine? A qualitative analysis of social media in Germany
por: Fieselmann, Jana, et al.
Publicado: (2022)

COVID-19 vaccine booster in healthcare workers - reasons for refusing
por: Cunha, R., et al.
Publicado: (2022)

Bosentan-based, treat-to-target therapy in patients with pulmonary arterial hypertension: results from the COMPASS-3 study
por: Benza, Raymond L., et al.
Publicado: (2017)

The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension
por: Wronski, Samantha L., et al.
Publicado: (2019)

Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine
por: Douwes, Johannes M., et al.
Publicado: (2022)

Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag
por: Hinkamp, Colin, et al.
Publicado: (2022)

Saudi experience in the management of pulmonary arterial hypertension; the outcome of PAH therapy with the exclusion of chronic parenteral prostacyclin
por: Idrees, Majdy, et al.
Publicado: (2015)

Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy
por: Abu‐Rmaileh, Muhammad, et al.
Publicado: (2023)

Reasons for Refusing Laser-Assisted in Situ Keratomileusis in a Pakistani Population
por: Hashmani, Sharif, et al.
Publicado: (2017)

Why do parents refuse childhood vaccination? Reasons reported in Finland
por: Nurmi, Johanna, et al.
Publicado: (2021)

Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension
por: Davey, Ryan, et al.
Publicado: (2017)

Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy
por: Knudsen, Lars, et al.
Publicado: (2011)

5613401 SICKLE CELL DISEASE GENOMICS OF AFRICA (SICKLEGENAFRICA) NETWORK: QUALITATIVE INTERVIEW FINDINGS ON REASONS FOR REFUSAL OF BROAD CONSENT
por: Osae-Larbi, J.A., et al.
Publicado: (2023)

Identifying Patients with Pulmonary Arterial Hypertension Using Administrative Claims Algorithms
por: Mathai, Stephen C., et al.
Publicado: (2019)

UNDERSTANDING THE REASONS FOR THE REFUSAL OF CHOLECYSTECTOMY IN PATIENTS WITH CHOLELITHIASIS: HOW TO HELP THEM IN THEIR DECISION?
por: PERON, Adilson, et al.
Publicado: (2014)

Reasons for acceptance or refusal of Human Papillomavirus Vaccine in a California pediatric practice
por: Brown, Brandon, et al.
Publicado: (2017)

COVID-19 Among Youth in Israel: Correlates of Decisions to Vaccinate and Reasons for Refusal
por: Gewirtz-Meydan, Ateret, et al.
Publicado: (2022)

Risk stratification and medical therapy of pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2019)

Vaccine hesitancy: An overview on parents' opinions about vaccination and possible reasons of vaccine refusal
por: Facciolà, Alessio, et al.
Publicado: (2019)

Reasons for refusal among patients with tuberculosis and their household contacts to participate in an observational cohort study
por: Raghupathy, Kalaivani, et al.
Publicado: (2021)

Reasons for COVID-19 vaccine refusal among people incarcerated in Canadian federal prisons
por: Ortiz-Paredes, David, et al.
Publicado: (2022)

Reasons for parental refusal of human papillomavirus vaccine during the COVID-19 pandemic in 2020
por: Abouelella, Dina K., et al.
Publicado: (2023)

Postplacental Placement of Intrauterine Devices: Acceptability, Reasons for Refusal and Proposals to Increase its Use
por: Kraft, Maria Beatriz de Paula Leite, et al.
Publicado: (2021)

Rapidly progressive pulmonary hypertension and right ventricular failure in a heart and kidney transplant recipient
por: Deicke, Matthew, et al.
Publicado: (2022)

Right ventricular afterload predicts long-term transition from parenteral to oral treprostinil in pulmonary arterial hypertension
por: Maestas, Travis, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0v7tmbu4cnukk7morejh0hf720